Canonical nuclear factor kappaB (NF-kB) activation signals stimulate nuclear translocation of p50:p65, replacing inhibitory p50:p50 with activating complexes on chromatin. C/EBP interaction with p50 homodimers provides an alternative pathway for NF-kB target gene activation, and interaction with p50:p65 may enhance gene activation. We previously found that C/EBPa cooperates with p50, but not p65, to induce Bcl-2 transcription and that C/EBPa induces Nfkb1/p50, but not RelA/p65, transcription. Using p50 and p65 variants containing the FLAG epitope at their N-or C-termini, we now show that C/EBPa, C/EBPa myeloid oncoproteins, or the LAP1, LAP2, or LIP isoforms of C/EBPb have markedly higher affinity for p50 than for p65. Deletion of the p65 transactivation domain did not increase p65 affinity for C/EBPs, suggesting that unique residues in p50 account for specificity, and clustered mutation of HSDL in the "p50 insert" lacking in p65 weakens interaction. Also, in contrast to Nfkb1 gene deletion, absence of the RelA gene does not reduce Bcl-2 or Cebpa RNA in unstimulated cells or prevent interaction of C/EBPa with the Bcl-2 promoter. Saturating mutagenesis of the C/EBPa basic region identifies R300 and nearby residues, identical in C/EBPb, as critical for interaction with p50. These findings support the conclusion that C/EBPs activate NF-kB target genes via contact with p50 even in the absence of canonical NF-kB activation and indicate that targeting C/EBP:p50 rather than C/EBP:p65 interaction in the nucleus will prove effective for inflammatory or malignant conditions, alone or synergistically with agents acting in the cytoplasm to reduce canonical NF-kB activation. Mol Cancer Res; 9(10); 1395-405. Ó2011 AACR.
Introduction
Nuclear factor kappaB (NF-kB) is implicated in the regulation of genes encoding inflammatory cytokines such as interleukin (IL) 2, IL-6, IL-8, and granulocyte macrophage colony-stimulating factor, or regulators of apoptosis, such as bcl-2 and Bcl-xL (1, 2) . Five NF-kB family members exist in mammalian cells, c-Rel, RelA/p65, RelB, NF-kB1/p50, and NF-kB2/p52. Each possesses an approximately 300 amino acid Rel homology domain (RHD) that mediates dimerization and DNA binding. The p50:p65 and p50:p50 complexes are the most common subunit combinations found in most cell types. p65 has a C-terminal transactivation domain (TAD) lacking in p50, allowing the p50:p65 heterodimer to activate genes in association with coactivators such as p300 whereas p50 homodimers often repress transcription via interaction with histone deacetylase (HDAC) 1 (3, 4) . p65 is sequestered in the cytoplasm by a series of IkB proteins. These bind the C-terminal segment of the RHD that contains the nuclear localization sequence. Canonical activation of p65, by a variety of stimuli, depends on phosphorylation of IkB by IkB kinases (IKK) followed by its ubiquitination and proteasomal degradation (5) . Notably, p50:p50 binds DNA even in unstimulated cells, reflecting the finding that IkB has approximately 60-fold lower affinity for p50 than for p65 (3, 6) .
We have provided evidence indicating that C/EBPa, C/EBPa variants associated with acute myeloid leukemia (AML), or C/EBPb cooperate with NF-kB p50 to activate the murine Bcl-2 and Flip genes to inhibit apoptosis via the intrinsic and extrinsic pathways (7, 8) . Importantly, this cooperative gene activation does not require DNA binding by the C/EBP proteins. Approximately, 10% of human AML cases harbor point mutations in the CEBPA genes. One allele often harbors an N-terminal mutation leading to expression of a truncated p30 isoform that retains an intact DNA-binding basic region (BR) leucine zipper (LZ) or bZIP domain that acts as a dominant-negative protein due to its weakened TAD whereas the other allele in the same patient often harbors an in-frame insertion or deletion in the LZ that prevents dimerization or DNA binding. These C/EBPaLZ variants retain the ability to activate transcription and inhibit apoptosis in cooperation with NF-kB p50 (7, 8) . The finding that CEBPA leucine zipper mutations associated with human AML are always in-frame and so retain the ability to induce Bcl-2, Mcl-1, and Flip expression provides a powerful biological "experiment of nature," indicating the potential importance of C/EBP:NF-kB interaction in cancer.
Several lines of evidence suggest that interaction with p50 rather than p65 is most critical for transcriptional synergy between C/EBP proteins and NF-kB complexes. C/EBPa or a C/EBPaLZ oncoprotein each cooperate with p50, but not p65, for human BCL-2 promoter activation; C/EBPa coimmunoprecipitates with endogenous p50 more effectively than endogenous p65 in 2 myeloid leukemia cell lines; mutation of the C/EBPa BR weakens interaction with p50 but not p65 and prevents endogenous Bcl-2 gene induction and inhibition of apoptosis; and germ line deletion of the Nfkb1 gene encoding the p50 subunit diminishes bcl-2 expression and chromatin immunoprecipitation (ChIP) of endogenous C/EBPa on the Bcl-2 promoter (7, 8) . Moreover, C/EBPs displace HDAC1 or HDAC3 from p50 bound to the Flip promoter to enable gene activation (9) .
Herein, we show that C/EBP proteins preferentially interact with NF-kB p50 compared with p65 using Nor C-terminally FLAG tagged p50 or p65 in coimmunoprecipitation (co-IP) reactions to uncover a consistently striking difference in affinity. Deletion of the p65 TAD did not increase affinity for C/EBPs, suggesting that amino acid differences in the p50 versus p65 RHD accounts for the increased affinity of p50 for C/EBP proteins. In addition, germ line deletion of floxed RelA/p65 alleles did not reduce Bcl-2 expression or interaction of C/EBPa with the Bcl-2 promoter, in contrast to findings with Nfkb1/p50 gene deletion. These observations support the idea that C/EBPs can induce NF-kB target genes even in the absence of canonical p65 activation via interaction with otherwise repressive p50:p50 complexes on chromatin. In addition, we have localized key residues in the C/EBPa BR required for interaction with p50 as well as a cluster of residues in p50 but lacking in p65 that contribute to interaction with C/EBPa. The implications of these findings for regulation of NF-kB target genes in normal or malignant cells and for the development of inhibitors of C/EBP:NF-kB interaction to treat AML and additional malignancies will be discussed.
Materials and Methods

Plasmids
The cDNAs encoding C/EBPa, C/EBPb, CMV-C/ EBPap30, or 4 C/EBPaLZ variants were inserted downstream of the cytomegalovirus (CMV) promoter in pGEM/ CMV. CMV-C/EBPabZIP and CMV-p50 were previously described (7, 10) ; CMV-p65, CMV-C-p50, and CMV-Cp65, the latter 2 expressing p50 or p65 with an in-frame Cterminal FLAG tag, were obtained commercially (Addgene), and CMV-N-p50 or CMV-N-p65 were generated by ligating the p50 or p65 cDNAs, with the endogenous initiating methionine deleted, downstream of an initiating methionine, the FLAG epitope, and a ClaI site encoding isoleucineaspartic acid (M-DYKDDDDK-ID). CMV-N-p50D356 and CMV-N-p65D297 were generated by PCR from the full-length proteins with addition of a stop codon. To generate C/EBPa BR mutants while avoiding PCR of the highly GC-rich C/EBPa cDNA, the codons for amino acids 270 and 271 were first replaced with a KpnI site via sitedirected mutagenesis, changing glycine-alanine to glycinethreonine. DNA encoding the 87 residue bZIP domain and subsequent stop codon, with a 5
0 KpnI site and a 3 0 XhoI site, were then synthesized (Blue Heron) and ligated downstream of the introduced KpnI site, and the resulting variant cDNAs were positioned downstream of the CMV promoter in pGEM/CMV. CMV-p50 was subjected to site-directed mutagenesis to generate clustered point mutants or to replace deleted segments with a KpnI site. All DNA constructs were confirmed by DNA sequencing.
Cell culture, co-IP, and Western blotting 293T cells were grown in Dulbecco's Modified Eagle's Medium with 10% FBS. Subconfluent 293T cells in 100 mm dishes were transiently transfected with 5 mg CMV expression vectors and 12 mL Lipofectamine 2000 (Invitrogen) per the manufacturer's instructions. Cell extracts were prepared 2 days later by washing twice with PBS, followed by rotation at 4 C for 20 minutes with 1,000 mL of 0.5% Triton X-100, 150 mmol NaCl, 1 mmol/ L EDTA, 20 mmol Tris (pH: 7.5), 1 mmol/L phenylmethylsulfonyl fluoride, and a cocktail of protease inhibitors (Sigma). The lysates were then briefly sonicated and clarified at 14,000 Â g for 10 minutes, and the supernatants were precleared with 50 mL of 50% protein A-Sepharose. Supernatants expressing C/EBP proteins (500 mL) and NFkB proteins were combined and 1% was saved as input. NF-kB lysate volumes were chosen to approximately match NF-kB protein inputs based on FLAG Western blotting. Total volume of each C/EBP:NF-kB mixture was brought to 1,000 mL using mock lysate, and this solution was then incubated with 1.2 mg primary antiserum or rabbit Ig together with 30 mL protein A-Sepharose overnight at 4 C. For FLAG IP, 30 mL agarose beads conjugated to M2-anti-FLAG monoclonal antibody or to mouse Ig as a control (Sigma) were used. The beads were then washed thrice with lysis buffer, and the samples were eluted in Laemmli sample buffer and subjected to Western blotting as described (11) . Antibodies employed were C/EBPa (14AA) for IP, C/EBPa (C-18) for Western blotting, C/EBPb (C19), or NF-kB p50 (NLS) from Santa Cruz Biotechnology, and anti-FLAG M2 antibody or anti-b-actin AC-15 from Sigma. All co-IP results shown are representative of at least duplicate experiments.
Gel shift analysis and reporter assay
Nuclear extracts were prepared from 293T cells transfected 2 days earlier with CMV expression vectors and subjected to gel shift analysis using annealed, double-stranded oligonucleotides containing either a consensus kB site or a C/EBP-binding site from the neutrophil elastase promoter, as described (12) . The sense strands of the gel shift probes containing 4 bp 5 0 overhangs, with binding sites underlined were kB: 5 0 -GTACGTAGGGGACTTTCC-GAGCTCGAGATCCTATG-3 0 and NE-C/EBP: 5 0 -TCGAGGCCAGGATGGGGCAATACAACCCG-3 0 . Plasmid (kB) 5 -LUC, containing 5 kB sites, 5 0 -GGGACTTTCC, upstream of a TATA box, initiation site, and the luciferase cDNA (PathDetect System and Agilent Technologies), was transiently transfected into 293T cells along with CMV vectors expressing NF-kB subunits and CMV-bGal as internal control. Luciferase and b-galactosidase activities were assessed 2 days later as described (13) .
Murine marrow isolation, RNA analysis, and ChIP
C57Bl/6 mice harboring floxed p65 alleles (14) were bred with C57Bl/6 Mx1-Cre mice (Jackson Laboratories) to generate p65(f/f);Mx1-Cre mice or p65(f/f) littermates. These mice were injected with 400 mg copolymer of polyinosinic and polycytidylic acids [poly(I)poly(C)] intraperitoneally every other day for 7 injections, and 5 weeks after the first injection, bone marrow cells were collected from the femurs by flushing with PBS. After red cell lysis with NH 4 Cl, cells were placed in Laemmli sample buffer for Western blotting or total cellular RNA was obtained using the Nucleospin RNA II Kit, in the presence of RNase-free DNase (Macherey-Nagel). First-strand cDNA was generated from 1 mg RNA using the ImProm II Reverse Transcriptase System (Promega) with random hexamer primers. Quantitative real-time PCR was carried out using the iQ SYBR Green Supermix and the iCycler iQ Real Time PCR Detection System (Bio-Rad Laboratories). Each sample was assayed in triplicate, and each experiment was repeated at least 3 times. Amplification of mouse large ribosomal subunit (mS16) RNA was used as a reference to standardize between samples. cDNA generated without reverse transcriptase did not yield detectable products. Primers employed were Bcl2-F:
0 . In addition, 7 Â 10 6 marrow mononuclear cells were subjected to ChIP using C/EBPa or p65 antisera or rabbit Ig followed by real-time PCR for the Bcl-2 P2 promoter, as described (8), or for Bcl-2 intron 5 as a control, using the following primers: P2-F:
Results
C/EBPa and C/EBPb have increased affinity for NF-kB p50 compared with p65
To enable direct comparison of C/EBP affinity for NF-kB p50 versus p65, we used p50 and p65 variants containing the FLAG epitope at their N-or C-termini, as diagrammed Figure 1 . NF-kB p50 has higher affinity than p65 for C/EBPa or C/EBPb. A, diagram of N-or C-terminal FLAG-tagged p50 or p65 (top). Total cellular proteins from 293T cells transfected with 1 to 5 mg of CMV vectors expressing these 4 proteins were subjected to Western blotting (WB) using FLAG antibody (bottom). DNA amounts were chosen to allow expression of similar amounts of each NF-kB protein. B, 293T extracts expressing similar levels of N-terminally FLAG tagged (NFLAG) p50 or p65 or C-terminally tagged (CFLAG) p50 or p65 were combined with equal volumes of C/EBPa expressed in a separate lysate and subjected to IP with FLAG antibody or mouse Ig control followed by Western blotting for C/EBPa (top) or to IP using C/EBPa antiserum or rabbit Ig followed by WB with FLAG antibody (bottom). I, 1% input; Ig, control IP; Ab, antibody IP. C, experiments were carried out (as in B), using extracts expressing C/EBPb rather than C/EBPa. Positions of the long LAP1 and LAP2 (LAP) and short (LIP) C/EBPb isoforms resulting from alternative translation initiation sites are shown.
( Fig. 1A, top) . Use of the FLAG epitope allows uniform immunoprecipitation (IP) and direct control of p50 and p65 inputs into co-IP reactions. Use of the FLAG antibody for IP also minimizes antibody contact with residues in p50 or p65 that may interact with C/EBP proteins and interference by the antibody is further alleviated if consistent results are obtained with use of both N-and C-terminally tagged p50 in comparison with similarly tagged p65. CMV expression vectors, adjusted on the basis of preliminary experiments to allow similar levels of NF-kB protein expression, were transiently transfected into separate dishes of 293T cells, and expression of N-p50, N-p65, C-p50, and C-p65, representing N-or C-terminally FLAG-tagged p50 or p65, were compared by Western blotting using the FLAG antibody (Fig. 1A, bottom) . N-p50 was expressed at a similar level as N-p65 whereas C-p50 was expressed at approximately a 2-fold lower level than C-p65 in these extracts. Adjustment in NF-kB lysate volumes were then made so that approximately matched amounts of these NF-kB isoforms were mixed with lysate containing exogenously expressed C/EBPa, and IP was carried out with FLAG antibody followed by Western blotting for C/EBPa (Fig. 1B, top) . Although both N-p50 and C-p50 readily interacted with C/EBPa, with signal in the antibody lane comparable with 1% input, no interaction with p65 was evident on this exposure, though weak interaction was evident on longer exposures (not shown). In addition, a reciprocal IP was conducted with the same protein mixtures, with IP conducted with C/EBPa antiserum followed by Western blotting with FLAG antibody (Fig. 1B, bottom) . In the input lanes, N-p50 was expressed at a mildly higher level than N-p65, but IP of C/EBPa as a percentage of input was much higher for N-p50. C-p50 was expressed at a lower level than C-p65 in the input lanes, and yet in both absolute terms and as a percentage of input, IP of C/EBPa was much higher with C-p50. Of note, we detect strong co-IP between p50 and N-p65 expressed under similar conditions (9) . Thus, as assessed using 4 different reaction conditions, namely use of N-or C-terminally tagged NF-kB subunits and use of FLAG or C/EBPa antibody for IP, affinity of C/EBPa for NF-kB p50 was much higher than for p65.
We found that C/EBPa harboring clustered mutations in its BR has greatly reduced affinity for p50 (7) , and the C/EBPa and C/EBPb BRs are highly conserved (29 of 35 residues identical). We therefore also compared the affinity of C/EBPb for N-or C-terminally FLAG-tagged p50 or p65. C/EBPb is expressed in 3 alternate translational forms termed LAP1, LAP2, and LIP, 296, 275, and 145 residues, respectively, each of which retain the C-terminal bZIP domain. IP with FLAG antibody followed by Western blotting for C/EBPb shows that each C/EBPb isoform has much increased affinity for N-p50 or C-p50 compared with N-p65 or C-p65 (Fig. 1C, top) . Electrophoresis on a 12% rather than a 10% acrylamide gel and for a longer time period better resolved the closely migrating LAP1 and LAP2 isoforms and confirmed that these as well as the LIP isoform of C/EBPb bind N-p50 with substantially higher affinity than N-p65 ( Supplementary Fig. S1A ). Also, reciprocal IP with C/EBPb antiserum followed by Western blotting using FLAG antibody provided additional results consistent with the conclusion that C/EBPb, like C/EBPa, has much higher affinity for NF-kB p50 than for NF-kB p65 (Fig. 1C, bottom) .
Although it is unlikely that both an N-and C-terminal FLAG epitope would directly interfere with C/EBP binding or indirectly disrupt the structure of p65, we carried out gel shift reactions using untagged p65, N-p65, or C-p65 and a radiolabeled consensus kB site ( Fig. 2A, lanes 1, 2, 7 , and 8) as well as untagged p50, N-p50, or C-p50 ( Fig. 2A, lanes 4 , 5, 9, and 10). Although there was some degradation of C-p65, the FLAG tag did not prevent proper folding, dimerization, and DNA binding when placed at the N-or C-terminus of p65 or p50. In addition, untagged p65, N-p65, and C-p65 were compared for their ability to activate a reporter containing 5 consensus kB sites linked to a minimal promoter and the luciferase reporter, with Figure 2 . DNA binding and transactivation by modified p50 and p65 proteins. A, 12 mg of 293T nuclear extracts expressing the indicated p50 or p65 proteins after transient transfection were subjected to electrophoretic mobility shift assay (EMSA) with 1 ng of a radiolabeled oligonucleotide containing a consensus kB site. B, 293T cells in 60 mm dishes were transiently transfected with 500 ng (kB) 5 -LUC, 1 ng CMV-bGal, 10 ng CMV-p50, and 100 ng of empty CMV vector or CMV vectors encoding p65, N-p65, or C-p65. Luciferase and b-galactosidase activities were determined 2 days later. Shown are mean and standard error of fold activation from 3 determinations by p65, N-p65, or C-p65 relative to empty CMV vector, the activity of which was set to 1.0 in each experiment.
CMV-bGal serving as an internal control plasmid. Relative to p50 plus empty CMV vector, addition of untagged p65, N-p65, or C-p65 increased reporter activity similarly, by 16-to 24-fold (Fig. 2B ). Together these data indicate that addition of the FLAG epitope to the N-or the C-terminus of p65 did not alter p65 protein folding to enable dimerization, DNA binding, and transactivation.
C/EBPa AML oncoproteins have increased affinity for NF-kB p50 compared with p65
We also compared the affinity of NF-kB p50 versus p65 for the 2 categories of C/EBPa AML oncoproteins. First, the N-terminally truncated C/EBPa p30 protein, lacking residues 1 to 117 of the 359 residue C/EBPa, was mixed with N-p50, N-p65, C-p50, or C-p65 and subjected to IP with FLAG antibody followed by Western blotting for C/EBPa p30 (Fig. 3A) . Regardless of whether the FLAG epitope was N-or C-terminal, C/EBPa p30 showed higher affinity for NF-kB p50 than for p65. Second, we used a similar approach to compare the affinity of 4 different, patient-derived C/EBPaLZ oncoproteins for p50 versus p65 ( Fig. 3B and C) . These C/EBPa variants, designated 3901, 3820, J3, and K6, had previously been evaluated for their ability to induce bcl-2 protein expression and to inhibit apoptosis in Ba/F3 cells, with K6 showing much less activity in these assays than the other 3 oncoproteins (7). Correlating with these prior functional findings, 3901, 3820, and J3 each bound p50 with significantly higher affinity that p65 whereas the K6 C/EBPaLZ oncoprotein had much reduced affinity for NF-kB p50 in comparison with the other 3 C/EBPaLZ oncoproteins.
Removal of the p65 TAD does not increase its interaction with C/EBPa or C/EBPb
Increased affinity of C/EBPa for NF-kB p50 compared with p65 may result either from amino acid differences between their respective N-terminal RHDs or from interference by the C-terminal p65 TAD. To evaluate these 2 possibilities, we generated a truncation mutant of N-p65 designated N-p65D297 lacking its 254 residue TAD but retaining its entire RHD as well as 17 more N-terminal residues. For comparison, we developed an analogous truncation mutant of p50, N-p50D356, lacking 77 C-terminal residues. A diagram of these truncated proteins and their wild-type, N-terminally FLAG-tagged counterparts is shown (Fig. 4A, top) . Both N-p65D297 and N-p50D356 bound a consensus kB site in gel shift analysis using nuclear extracts from 293T cells expressing these proteins (Fig. 2A, lanes 3  and 6) . These 4 proteins were expressed in 293T cells using equivalent amount of CMV expression vectors, and total cellular extracts were prepared for co-IP with C/EBPa. Western blot analysis of lysates expressing the NF-kB proteins indicated that N-p65D297 was expressed 2-to 3-fold higher level than p65 whereas N-p50D356 was expressed approximately 2-fold lower level than p50 (Fig. 4A, bottom ). co-IP was then conducted, adjusting extract volumes to approximately equalize NF-kB input and using C/EBPa or C/EBPb extracts isolated from separate dishes of 293T cells to ensure equal C/EBP input to each co-IP ( Fig. 4B and C) . Removal of the p65 TAD did not increase interaction of p65 with C/EBPa or C/EBPb whereas truncation of p50 to the homologous location did not significantly alter its interaction with either C/EBP protein. These data suggest that the p65 TAD does not sterically hinder contact of C/EBPa with the p65 N-terminal region but that amino acid differences between the N-terminal segments of p50 and p65, mainly consisting of their RHDs, account for reduced affinity of p65 for C/EBP proteins.
Identification of a cluster of residues unique to NF-kB p50 required for C/EBPa binding The p50 and p65 RHDs are highly homologous and can be almost entirely coaligned with the exception that the p50 RHD contains a 30 amino acid segment referred to as the Figure 3 . NF-kB p50 has higher affinity than p65 for C/EBPap30 or C/EBPaLZ myeloid oncoproteins. A, 293T extracts expressing matched levels of N-terminally FLAG tagged (NFLAG) p50 or p65 or C-terminally tagged (CFLAG) p50 or p65 were combined with equal volumes of a separate extract expressing C/EBPap30 and subjected to IP with FLAG antibody or Ig control followed by Western blotting for C/EBPa. B, extracts expressing matched levels of NFLAG p50 or p65 were combined with equal volumes of extracts expressing 1 of 4 patient-derived C/EBPaLZ variants (3901, 3820, J3, or K6) followed by IP with FLAG antibody or Ig control and WB for C/EBPa. C, similar analysis was conducted using CFLAG p50 or p65.
"p50 insert," mainly comprising a loop between 2 a-helices, a1 and a2 (Fig. 5A) . As a first step toward localizing p50 residues that contact C/EBPa, we sought to determine whether the "p50 insert" contributes to C/EBPa:p50 interaction using 3 deletion and 2 clustered point mutant variants, as diagramed. The deletion variants proved unstable and could not be further evaluated. Mutant 1, with HSDL (residues 170-173) changed to AAAA, interacted much more weakly than wild-type p50 with C/EBPa in a co-IP reaction despite its expression at levels exceeding p50 whereas mutant 2 retained nearly full affinity for C/EBPa (Fig. 5B) . Mutants 1 and 2 each bound a radiolabeled kB site with affinity similar to wild-type p50 (Fig. 5C ), indicating that these p50 variants fold properly, allowing them to homodimerize and bind DNA. These data indicate that residues HSDL within the loop region of the "p50 insert" and absent in NF-kB p65 contribute to interaction of NF-kB p50 with C/EBPa.
Identification of key residues in the C/EBPa basic region required for NF-kB p50 binding
The C/EBPa bZIP domain is sufficient for interaction with p50 (8, 15) . We compared full-length, 359 residue C/ EBPa and its 89 residue, C-terminal bZIP domain (abZIP) for strength of interaction with N-p50 by co-IP followed by Western blotting using a C-terminal C/EBPa antiserum (Fig. 6A) . Relative to input samples, interaction of p50 with abZIP was not weaker but, in fact, stronger than with the full-length protein, consistent with the idea that all relevant protein contacts are made with the bZIP domain. In addition, we compared the affinity of full-length C/EBPa or abZIP for N-p65 ( Supplementary Fig. S1B ). These data show that deletion of residues 1 to 269 of C/EBPa did not increase p65 affinity, arguing against steric hindrance due to contact between the p65 TAD and this N-terminal region of C/EBPa. An 88 residue, C-terminal bZIP domain Figure 4 . Deletion of the p65 TAD does not increase its affinity for C/EBPa or C/EBPb. A, diagram of N-terminally FLAG tagged p65, p65D297, p50, and p50D356 (top). Total cellular proteins from 293T cells transfected with CMV vectors expressing these 4 proteins were subjected to Western blotting using FLAG antibody (bottom). B, extracts expressing matched levels of these proteins were combined with equal volumes of an extract expressing C/EBPa, followed by IP with FLAG antibody or Ig and Western blotting for C/EBPa. The locations of C/EBPa and of nonspecific heavy chain cross-reactivity are shown (hc). C, similar analysis was conducted using C/EBPb, the upper band representing the LAP isoforms and the lower band LIP. Both panels in B or C are from the same autoradiograph exposure. Figure 5 . A cluster of residues in the "p50 insert" is required for interaction with C/EBPa. A, diagram of NF-kB p50 amino acids 147 to 202, including a-helices a1 and a2 and the intervening loop. Residues corresponding to the "p50 insert" present in NF-kB p50, but not p65, are shown as are the locations of 2 clustered point mutants (mut1 and mut2), in which indicated residues were changed to alanine, and 3 deletion mutants (D1, D2, and D12), in which the bars indicate deleted segments. D1 lacks residues 147 to 180, D2 lacks residues 162 to 203, and D12 lacks residues 147 to 203. B, wild-type p50 or its mut1 or mut2 variants were subjected IP with p50 antiserum followed by Western blotting with C/EBPa antiserum (left). Also, shown are the relative expression of p50, mut1, and mut2 in the input lysates (right). The 3 deletion variants failed to express in 293T cells and could not be analyzed similarly. C, NF-kB p50 and its mut1 or mut2 variants were assessed for homodimerization and DNA binding to a kB site using the EMSA.
derived from C/EBPb also bound N-p50 with increased affinity compared with N-p65 ( Supplementary Fig. S1C ).
The C/EBPa LZ domain is not essential for binding to p50, as swapping the GCN4 LZ for the C/EBPa LZ in the context of full-length protein only mildly reduces C/EBPa: p50 interaction (8) . In addition, as shown herein, inserting 8 or 5 residues between the BR and LZ protein domains, as occurs in C/EBPaLZ oncoproteins 3820 or J3, does not substantially alter interaction with p50. This is particularly noteworthy, as the bZIP domain is a continuous a-helix with a 7 amino acid helical repeat, and so insertion of 8 or 5 residues would not only distance the BR from the LZ but would also rotate them relative to each other. Mutant 3901 also retains p50 binding despite deletion of 1 residue between the BR and LZ. As a step toward designing a small molecule that might interfere with C/EBPa:p50 interaction, we therefore sought to further define the residues within the C/EBPa BR that contact p50. The amino acid sequence of the BR, a diagram of 18 mutant BR variants evaluated, and a summary of the effect of these alterations on interaction with p50, as assessed by co-IP, and on DNA binding, as measured by electrophoretic mobility shift assay using a radiolabeled C/EBP-binding site, is shown in Figure 6B . With the exception of the C/EBPa (BR3) and C/EBPa (R300G) variants, all indicated residues in each mutant were changed to alanine. The abcdefg position of each residue in the a-helix is shown as is a wheel diagram of the a-helix. Mutants A (deg), B (be), C (gad), and D (abe) were designed so that the altered residues would be adjacent on the cylindrical surface of the a-helix. Mutant E (degbe) is a combination of mutants A and B, mutant F (deggad) is a combination of mutants A and C, Figure 6 . Saturating C/EBPa BR mutagenesis to identify residues required for interaction with p50. A, 293T extracts expressing C/EBPa (lanes 1-3) or the bZIP domain of C/EBPa (abZIP, lanes 4-6) were incubated with equal volumes of an extract expressing N-p50, followed by IP using FLAG antibody or Ig control and Western blotting using an antiserum recognizing the C-terminus of C/EBPa. B, sequence of the C/EBPa BR, diagram of BR mutants analyzed for interaction with p50 or DNA, and summary of the experimental findings. In each variant, indicated residues were changed to alanine. "B" denotes residues contacting DNA bases and "P" denotes residues contacting DNA phosphates in the cocrystal structure. abcdefg indicates the position of each residue in the BR a-helical structure, a diagram of which is shown as an insert. C, 293T extract expressing NF-kB p50 was combined with extracts expressing C/EBPa or the indicated variants, followed by IP with p50 antiserum and subsequent Western blotting for C/EBPa. D, 12 mg of 293T nuclear extracts expressing C/EBPa or the indicated variants were subjected to EMSA using 1 ng of a radiolabeled oligonucleotide containing a C/EBP-binding site (top). The nuclear extracts were subjected to Western blotting using C/EBPa antiserum (bottom).
and mutant L (begad) is a combination of mutants B and C. Representative co-IP and DNA-binding data are shown for wild-type C/EBPa and for each mutant variant (Fig. 6C  and D and Supplementary Fig. S2 ).
C/EBPa (BR3) contains 4 altered amino acids and was previously found not to induce bcl-2 expression or bind p50; and in that same study, individual mutation of each of these 4 residues uncovered R300G as the alteration critical for bcl-2 induction and prolonged Ba/F3 survival upon IL-3 withdrawal (7). Consistent with these functional data, we now find that R300G does not bind p50. As glycine disrupts a-helical structure, the R300G mutation might have disrupted distant folding. We therefore also generated C/EBPa (R300A) and find that as with R300G binding of p50 to this variant is lost. Saturating mutagenesis of the remainder of the BR identified a 6 amino acid cluster, RERNNI, common to mutant G and mutant H, required for interaction with p50. Mutant H was divided into mutants H1 (dea) and H2 (fgb), each containing nonoverlapping, triple alanine mutations derived from RERNNI chosen to be on the same surface of the a-helix. The H1 and H2 variants each had reduced affinity for p50, in comparison with wild-type C/EBPa. Finally, although mutants A, B, C, or L (B þ C) bound p50 well, the combination of A with B (mutant E) or to an even greater extent A with C (mutant F) led to a significant, reproducible reduction in p50 interaction.
None of the C/EBPa variants with significantly reduced affinity for p50 (R300G, R300A, or mutants E, F, G, H, H1, or H2) retained DNA-binding activity for a consensus C/EBP site, suggesting that the same surface of the BR a-helix that contacts DNA also binds p50. In the nuclear extracts used for gel shift analysis, mutants A, E, H, and H1 were expressed at somewhat lower levels than the other variants as assessed by Western blot analysis; nevertheless, no evidence of DNA binding by these variants was evident even upon prolonged exposure of the gel shift autoradiographs (not shown).
Deletion of the gene encoding p65 does not reduce expression of C/EBPa or bcl-2
Mice lacking both copies of the Nfkb1 gene encoding NF-kB p50 are viable, and their marrow mononuclear cells have 3-fold reduction in C/EBPa protein and RNA levels, reduced binding of p50 and C/EBPa to the Bcl-2 promoter, and 4-fold reduced Bcl-2 RNA expression (8, 16) . Of note, mutation of a kB site located at À170 bp in the Bcl-2 P2 promoter reduces transactivation by C/EBPa or by the 3901 C/EBPaLZ variant that cannot directly bind DNA (8) . Homozygous deletion of the RelA/p65 gene encoding NF-kB p65 is embryonic lethal (17) . We bred mice containing loxP sites surrounding exon 5 to 8 of RelA/p65, encoding the majority of the RHD (14), with Mx1-Cre transgenic mice to generate p65(f/f);Mx1-Cre mice or control p65(f/f) littermates. Intraperitoneal injection of these mice with poly(I)poly(C) to induce Cre recombinase expression led to efficient loss of p65 protein and RNA from bone marrow mononuclear cells without reduction in C/EBPa protein or RNA or reduction in Bcl-2 RNA in unstimulated cells (Fig. 7A and B) . In addition, homozygous deletion of the RelA/p65 gene markedly reduced binding of p65 to the Bcl-2 P2 promoter, without affecting C/EBPa binding, as assessed by ChIP (Fig. 7C) . Providing a negative control, no binding of these factors was seen within intron 5 of Bcl-2. These data and our prior findings are consistent with the idea that p50, but not p65, is required for regulation of Cebpa gene transcription and that interaction of C/EBPa with chromatin-bound p50, but not p65, is required for activation of the gene encoding bcl-2.
Discussion
NF-kB is a central mediator of the inflammatory response, both within the tumor microenvironment and in tumor cells, and induces expression of growth factors and angiogenic factors that contribute to cancer induction and Figure 7 . Homozygous deletion of the RelA/p65 gene does not affect C/EBPa or bcl-2 expression in marrow cells. A, total cellular proteins isolated from the marrow of p65(f/f) or p65(f/f);Mx1-Cre mice exposed to poly(I)poly(C) to delete the floxed alleles were subjected to Western blotting for p65, C/EBPa, or b-actin. B, total cellular RNA isolated from these cells was subjected to real time reverse transcriptase PCR analysis for Cebpa, Bcl-2, or RelA/p65 RNAs. The level of expression of each RNA isolated from mice lacking Mx1-Cre was set to 1.0, and relative expression of each RNA from p65(f/f);Mx1-Cre mice are shown as the mean and standard error from 3 separate mice in each group. C, marrow cells from p65(f/f) or p65(f/f);Mx1-Cre mice exposed to poly(I)poly(C) were subjected to ChIP using C/EBPa or p65 antiserum or rabbit Ig, followed by PCR analysis for binding to the Bcl-2 P2 promoter or intron 5. Percentage input is shown for each condition as the mean and standard error from 3 separate ChIP assays.
progression. In addition, NF-kB activates multiple antiapoptotic genes that may contribute further to malignant progression. Activation of NF-kB is common in AML (18) , several lymphoma subsets (19) (20) (21) , breast cancer (22, 23) , colorectal cancer (24) , prostate cancer (25, 26) , ovarian cancer (27) , malignant gliomas (28) , and additional malignancies. Antagonism of receptors, such as Her2, that mediate NF-kB activation or direct targeting of cytoplasmic IKKa or IKKb offer means to inhibit NF-kB activation in cancer (29, 30) . As an additional, potentially synergistic, therapeutic approach, we envision inhibition of NF-kB in the nucleus. In particular, we have defined an alternative pathway for induction of NF-kB target genes in which C/EBP proteins displace HDACs and potentially other corepressors from NF-kB p50:p50 homodimers (7) (8) (9) . In addition, interaction of C/EBPs with the p50:p65 complex may further induce NF-kB target genes. As p50 has much lower affinity for IkB than p65, p50:p50 homodimers exist in the nucleus of cells that lack canonical NF-kB activation (3) . Induction or activation of C/EBP proteins, as may occur during malignant progression, may enable their interaction with p50:p50 homodimers or p50:p65 heterodimers on chromatin. For example, N-or C-terminal C/EBPa mutants found in a subset of AML cases cannot bind DNA and so are defective in differentiation induction but retain the ability to induce NF-kB target genes via interaction with p50 (7) (8) (9) . In addition, C/EBPb is induced by nucleophosmin-anaplastic lymphoma kinase in anaplastic large-cell lymphomas (31), directly activates bcl-2 transcription in multiple myeloma (32) , and transforms normal mammary epithelium (33) , and C/EBPa or C/EBPb are induced or activated by TNF-a, AKT, or mitogen-activated protein kinases in hepatocellular, prostate, or breast carcinoma cells, where they potentially cooperate with NF-kB to inhibit apoptosis (34) (35) (36) (37) .
We previously found that NF-kB p50, but not p65, cooperates with C/EBPa to induce Bcl-2 gene transcription to inhibit apoptosis and that C/EBPa activates the promoter of the Nfkb1/p50 gene in cooperation with p50 but does not induce RelA/p65 RNA expression (7, 9 ). The present study shows that C/EBPa, C/EBPap30, or C/EBPaLZ oncoproteins, or the LAP1, LAP2, or LIP isoforms of C/EBPb bind NF-kB p50 with substantially greater affinity than NF-kB p65, thereby further focusing translational efforts on inhibition of the C/EBP:p50 rather than the C/EBP:p65 interaction. Use of FLAG-tagged p50 or p65 allowed their inputs to co-IP reactions to be monitored and approximately equalized, and expression of both N-and C-terminally tagged p50 or p65 proteins allowed us to control for potential interference by the FLAG epitope.
Underscoring the idea that C/EBPa interaction with p50 is critical for its antiapoptotic effect, C/EBPa (K6), the 1 C/EBPaLZ oncoprotein of 4 studied herein that bound p50 poorly, is the only one that does not induce bcl-2 or substantially inhibit apoptosis in Ba/F3 cells withdrawn from IL-3 (7). The present study further emphasizes the biological importance of C/EBP:p50 as compared with the C/EBP:p65 interaction by showing that homozygous deletion of the RelA/p65 gene in adult mice does not reduce bcl-2 or C/EBPa expression in bone marrow mononuclear cells or prevent endogenous C/EBPa interaction with the Bcl-2 promoter, in striking contrast to the effect of Nfkb1/p50 gene deletion (8, 16) . Also, C/EBPa stimulates Nfkb1/p50, but not RelA/p65, gene transcription, p50 binds and activates the Cebpa promoter, and mice lacking p50 have substantially reduced marrow C/EBPa protein and RNA levels (16) , establishing a positive feedback loop mediating expression of these 2 proteins.
Elevated affinity of C/EBPa or C/EBPb for p50 might have reflected interference by the p65 TAD. However, deletion of this C-terminal domain did not increase affinity of either C/EBP for p65. We therefore conclude that differences in the N-terminal domains of p50 and p65, which largely comprise their RHDs, accounts for stronger interaction of p50 with C/EBPs. Of note, the RHD is sufficient for interaction with the bZIP domain of C/EBPa or C/EBPb (15) . Although approximately one-third of the residues in the p50 and p65 RHDs are identical when aligned, and although there are additional conservative matches, many residues differ substantially. Of note, the p50 C-terminal truncation variant studied herein, Np50D356, is 59 residues longer than N-p65D297, which was deleted to a homologous position, in part, because the p50 RHD contains 30 consecutive internal residues known as the "p50 insert" lacking in the p65 RHD. p50 also has 21 residues N-terminal to the RHD lacking in p65 and several additional internal residues. We find that mutation of 4 residues, HSDL, within the loop region of the "p50 insert" strongly weakens interaction with C/EBPa. Future studies will focus on further delineating the p50 residues that mediate C/EBP:p50 interaction using both genetic and structural approaches.
In addition, we have further localized residues in C/EBPa that contact p50. First, we show that the C/EBPa bZIP domain has similar or perhaps greater affinity for p50 than does full-length C/EBPa, consistent with earlier work showing that introduction of 4 clustered point mutations in the BR of C/EBPa, the BR3 mutant prevents p50 binding (7) . When these 4 residues are mutated individually, only R300G reduces bcl-2 induction and protection from apoptosis upon IL-3 withdrawal (7). Correlating with these findings, we now show that R300G does not bind p50 and that R300A, avoiding disruption of the a-helix by glycine, also does not bind p50. The bZIP domain consists of the BR and adjacent LZ. Two lines of evidence suggest that the LZ does not make significant contacts contributing to affinity of C/EBPa for p50. First, swapping the yeast GCN4 LZ only mildly reduces C/EBPa:p50 interaction (8) . Second, the 3820 and J3 C/EBPa oncoproteins contain insertions of 8 or 5 residues between the BR and LZ, thereby distancing these domains and yet retain strong affinity for p50. We therefore conducted scanning alanine mutagenesis of the C/EBPa BR in the context of full-length C/EBPa. In addition to R300, we found that residues 289 to 294, RERNNI, contribute to p50 binding and that residues surrounding R300 also participate in C/EBPa interaction with p50. Residues VRS of mutant A are particularly implicated by the finding that mutant combinations A þ B or A þ C, but not B þ C, reduced p50 interaction. These data will assist interpretation of future protein biochemical studies, such as nuclear magnetic resonance or cocrystallization, designed to identify C/EBPa:p50 contacts.
Of note, RERNNI, R300, and residues surrounding R300 are identical in the BRs of C/EBPb and C/EBPd. C/EBPa BR residues that contact DNA in the reported cocrystal structure (38) are indicated in Figure 6B , where B denotes contact with bases in the major groove and P denotes contact with the phosphate backbone. The C/EBPa BR a-helix contacts specific DNA bases via residues on its cgda surface and also contacts phosphate residues via positions e and f. Mutants BR3, R300G, R300A, A, E, F, G, H, H1, and H2 each alter residues that contact DNA bases, thereby preventing DNA binding. C/EBPa BR variants that disrupt p50 binding also prevent C/EBPa DNA binding, suggesting that interaction of wild-type C/EBP protein with p50 may interfere with C/EBP DNA binding. However, it remains possible that residues, such as R300, can contact DNA and p50 simultaneously as we previously found that neither a kB nor a C/EBP DNA-binding site prevents C/EBPa:p50 co-IP, although this experiment may be complicated by rapid DNA on/off kinetics (8) . For a subset of genes, C/EBPs may bind DNA and then interact with nearby, DNA-bound p50 to synergistically stimulate gene activation, but C/EBPs may more commonly tether to DNA via p50:p50 homodimers or p50:p65 heterodimers to mediate cooperative activation of NF-kB target genes. In regulating Nfkb1 promoter activity, C/EBPa or C/EBPa oncoproteins tether to p50 bound to either of 2 kB sites to activate transcription without themselves directly binding DNA (9) , and there may be additional genes activated by C/EBPs through a similar mechanism. On the other hand, activation of the C-reactive protein (CRP) gene promoter involves synergistic C/EBPb and p50 DNA binding, potentially mediated by direct protein interaction, to overlapping kB and C/EBP DNA elements (39) . Identifying genes whose expression is mediated by C/EBP:p50 interaction and showing their relevance to human malignant transformation would further validate the utility of targeting the C/EBP:p50 interaction and is an additional subject of our ongoing investigations.
In summary, we find that C/EBP proteins have substantially higher affinity for NF-kB p50 than for p65, and that p65 gene deletion does not reduce marrow C/EBPa protein or RNA or Bcl-2 RNA expression in contrast to prior findings with p50 gene deletion, providing further support for our proposal that interaction of C/EBPs with p50:p50 or p50:p65 NF-kB complexes provides an alternative means to activate NF-kB target genes, even in cells lacking canonical NF-kB activation. In addition, these findings focus translational efforts on targeting the C/EBP:p50 interaction, and data herein contribute to such efforts by localizing interacting residues within the C/EBPa basic region and p50 and by showing that differences between the p50 and p65 N-terminal regions rather than the presence of the p65 TAD contributes to their substantially different affinities for C/EBP proteins.
